PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.
B cell epitope
CD4 T cell
CD8 T cell
IMM60
NY-ESO-1
PLGA nanoparticle
iNKT cell
peptide vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
12
2020
accepted:
28
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85-111, 117-143, and 157-165) derived from immunodominant regions of NY-ESO-1 were selected. These peptides have a wide HLA coverage and were efficiently processed and presented by dendritic cells
Identifiants
pubmed: 33717196
doi: 10.3389/fimmu.2021.641703
pmc: PMC7947615
doi:
Substances chimiques
Drug Carriers
0
Neoplasm Proteins
0
Peptide Fragments
0
peptide NY-ESO-1 157-165
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
641703Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Dölen, Gileadi, Chen, Valente, Creemers, Van Dinther, van Riessen, Jäger, Hruby, Cerundolo, Diken, Figdor and de Vries.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2015 Jun 15;194(12):6177-89
pubmed: 25957167
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25816-25827
pubmed: 31796596
Front Oncol. 2018 Sep 25;8:404
pubmed: 30319969
Int J Cancer. 2001 Jun 15;92(6):856-60
pubmed: 11351307
Int J Cancer. 2011 Dec 15;129(12):2836-46
pubmed: 21448901
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5290-9
pubmed: 26351680
J Immunol. 2003 Dec 1;171(11):6283-9
pubmed: 14634146
Front Immunol. 2020 Feb 21;11:276
pubmed: 32153583
Biomater Res. 2019 Nov 21;23:20
pubmed: 31832232
J Immunother. 2014 Feb-Mar;37(2):84-92
pubmed: 24509171
Eur J Immunol. 2014 Feb;44(2):500-10
pubmed: 24136200
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
Eur J Immunol. 2014 Aug;44(8):2230-7
pubmed: 24782127
Blood. 2009 Jan 8;113(2):370-6
pubmed: 18832653
Cancer Immunol Res. 2014 Dec;2(12):1230-44
pubmed: 25245536
J Immunol. 1996 Apr 1;156(7):2473-80
pubmed: 8786307
J Virol. 2008 Jan;82(1):86-95
pubmed: 17959670
J Immunol. 2006 May 15;176(10):5908-17
pubmed: 16670298
J Immunol. 2016 Jan 1;196(1):64-71
pubmed: 26608910
Blood. 2010 Jul 15;116(2):218-25
pubmed: 20430956
J Immunol. 2003 Nov 15;171(10):5140-7
pubmed: 14607913
Oncoimmunology. 2015 Aug 12;5(1):e1068493
pubmed: 26942088
Nat Rev Immunol. 2013 Feb;13(2):101-17
pubmed: 23334244
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
Oncoimmunology. 2016 Sep 9;5(10):e1216290
pubmed: 27853637
Nat Rev Immunol. 2009 Jan;9(1):28-38
pubmed: 19079136
J Exp Med. 2003 Jul 21;198(2):267-79
pubmed: 12874260
Int J Cancer. 2015 Mar 15;136(6):E590-601
pubmed: 25081390
J Clin Invest. 2002 Dec;110(12):1813-22
pubmed: 12488431
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11813-8
pubmed: 12186971
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
pubmed: 9050879
Eur J Immunol. 2008 Apr;38(4):1033-42
pubmed: 18350546
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Cancer Immunol Immunother. 2018 Feb;67(2):285-298
pubmed: 29094183
Oncoimmunology. 2020 Mar 17;9(1):1738813
pubmed: 33457086
J Transl Med. 2013 Oct 05;11:246
pubmed: 24093426
J Immunol Methods. 2002 Oct 1;268(1):35-41
pubmed: 12213341
Adv Cancer Res. 2006;95:1-30
pubmed: 16860654
Immunotherapy. 2015;7(4):411-39
pubmed: 25917631
Future Oncol. 2010 May;6(5):717-32
pubmed: 20465387
Small. 2018 Apr;14(15):e1703539
pubmed: 29493121
Cancer Immunol Res. 2014 Jan;2(1):37-49
pubmed: 24535937
Eur J Immunol. 2016 May;46(5):1224-34
pubmed: 26873393
Eur J Immunol. 1999 Oct;29(10):3112-21
pubmed: 10540322